Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Akari Therapeutics ADR (AKTX)

Akari Therapeutics ADR (AKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,678
  • Shares Outstanding, K 26,472
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,010 K
  • EBIT $ -19 M
  • EBITDA $ -19 M
  • 60-Month Beta 0.80
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9000 +5.56%
on 11/26/24
1.4583 -34.86%
on 12/03/24
-0.3500 (-26.92%)
since 11/22/24
3-Month
0.9000 +5.56%
on 11/26/24
3.8500 -75.32%
on 09/26/24
-2.2500 (-70.31%)
since 09/23/24
52-Week
0.9000 +5.56%
on 11/26/24
4.4000 -78.41%
on 07/26/24
-2.1000 (-68.85%)
since 12/22/23

Most Recent Stories

More News
Akari Therapeutics Announces Appointment of Samir R. Patel, M.D. as CEO and Abizer Gaslightwala to Board of Directors

Akari Therapeutics announces Samir R. Patel as CEO and Abizer Gaslightwala's appointment to the Board of Directors.Quiver AI SummaryAkari Therapeutics, Plc announced the appointment of Samir R. Patel,...

AKTX : 0.9500 (-2.06%)
Akari Therapeutics Announces Key Leadership Appointments

AKTX : 0.9500 (-2.06%)
Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer

Akari Therapeutics appoints Dr. Torsten Hombeck as CFO, strengthening leadership with expertise in biotechnology and finance.Quiver AI SummaryAkari Therapeutics, Plc announced the appointment of Dr. Torsten...

AKTX : 0.9500 (-2.06%)
Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer

AKTX : 0.9500 (-2.06%)
Akari Therapeutics Regains Full Nasdaq Compliance

AKTX : 0.9500 (-2.06%)
Akari Therapeutics Completes Merger with Peak Bio and Secures $3.2 Million in PIPE Financing

Akari Therapeutics secures $3.2 million in PIPE financing and a $50 million equity line of credit following its merger with Peak Bio.Quiver AI SummaryAkari Therapeutics, Plc has completed a merger with...

AKTX : 0.9500 (-2.06%)
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio

AKTX : 0.9500 (-2.06%)
Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger

AKTX : 0.9500 (-2.06%)
Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger

AKTX : 0.9500 (-2.06%)
PKBO : 0.0225 (-67.86%)
Akari Therapeutics Narrows Pipeline Focus

NEW YORK and LONDON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced...

AKTX : 0.9500 (-2.06%)

Business Summary

Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company's lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5,...

See More

Key Turning Points

3rd Resistance Point 1.0697
2nd Resistance Point 1.0417
1st Resistance Point 1.0059
Last Price 0.9500
1st Support Level 0.9421
2nd Support Level 0.9141
3rd Support Level 0.8783

See More

52-Week High 4.4000
Fibonacci 61.8% 3.0630
Fibonacci 50% 2.6500
Fibonacci 38.2% 2.2370
Last Price 0.9500
52-Week Low 0.9000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar